Posts in category Business Standard
Hong Kong Market ends tad lower (13-03-2024)
At closing bell, the benchmark Hang Seng Index fell by 11.39 points, or 0.07%, to 17,082.11. The Hang Seng China Enterprises Index sank 17.06 points, or 0.29%, to 5,932.46.
Government allocates Rs 500 crore for Electric Mobility Promotion Scheme (13-03-2024)
Powered by Capital Market - Live News
Shares plunge as broader market meltdown deepens, AMFI advisory spooks investors (13-03-2024)
The domestic stock markets plunged on Wednesday in a broad sell-off, as the recent meltdown in mid and small-cap stocks continued to wreak havoc. The benchmark Sensex crashed 906.07 points or 1.23% to settle at 72,761.89, while the Nifty 50 tumbled 338 points or 1.51% to close at 21,997.70.
INR Settles Slightly Lower Amid Massive Sell-Off In Domestic Equities (13-03-2024)
The Indian rupee declined by 5 paise to settle at 82.85 (provisional) against the US dollar on Wednesday, tracking a broad-based selloff in domestic markets. Indian shares fell sharply on Wednesday, with Fed rate cut uncertainty and ongoing selloff in the mid-cap and small-cap space keeping investors nervous. The benchmark S&P BSE Sensex hit an intraday low of 72,515.71 before recovering some lost ground to end the session down 906.07 points, or 1.23 percent, at 72,761.89. The broader NSE Nifty index settled 338 points, or 1.51 percent, lower at 21,997.70, after having tumbled to 21,905.65 earlier. At the interbank foreign exchange market, the local unit opened at 82.82 and witnessed an intra-day low of 82.91 and a high of 82.82 against the greenback during the trading session. Meanwhile, dollar index raced well above 103 in the previous session following firm US inflation reading that drove treasury yields and greenback alike. Currently, it trades at 102.88.
Popular Vehicles and Services IPO subscribed 45% (13-03-2024)
The offer received bids for 65.31 lakh shares as against 1.44 crore shares on offer.
Sebi board may ease IPO norms, approve same-day settlement framework (13-03-2024)
Exemption to certain FPIs from granular disclosures, passive funds from single co exposure also on anvil
Zydus Lifesciences launches cancer drug – IBYRA in India (13-03-2024)
In a significant stride towards making advanced cancer treatment accessible to all, Zydus has launched Olaparib, a PARP inhibitor, under the brand name IBYRA in India. The drug will target specific genetic mutations prevalent in certain types of cancers, paving the way for more tailored and effective treatment approach.
Nifty March futures trade at premium (13-03-2024)
NSE India VIX soared 5.82% as shares tumbled.
Zydus Life launches cancer drug in India (13-03-2024)
The drug maker announced that it has launched Olaparib, a PARP inhibitor, under the brand name IBYRA in India.
Quick Wrap: Nifty PSE Index registers a drop of 6.65%, NIFTY Crashes 1.51% (13-03-2024)
Powered by Capital Market - Live News